Corbus Pharmaceuticals (NASDAQ:CRBP) Receives New Coverage from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBPGet Rating) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Corbus Pharmaceuticals Trading Up 4.9 %

Shares of CRBP opened at $0.22 on Tuesday. The company has a current ratio of 4.81, a quick ratio of 4.81 and a debt-to-equity ratio of 0.23. Corbus Pharmaceuticals has a 12-month low of $0.19 and a 12-month high of $1.21. The firm has a 50-day moving average price of $0.25 and a 200 day moving average price of $0.31. The firm has a market capitalization of $27.03 million, a P/E ratio of -0.74 and a beta of 1.98.

Corbus Pharmaceuticals (NASDAQ:CRBPGet Rating) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Sell-side analysts forecast that Corbus Pharmaceuticals will post -0.23 EPS for the current year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC acquired a new position in Corbus Pharmaceuticals in the fourth quarter valued at about $112,000. Vident Investment Advisory LLC lifted its position in Corbus Pharmaceuticals by 66.2% in the first quarter. Vident Investment Advisory LLC now owns 255,146 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 101,659 shares during the last quarter. State Street Corp lifted its position in Corbus Pharmaceuticals by 10.7% in the first quarter. State Street Corp now owns 395,513 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 38,304 shares during the last quarter. Davy Global Fund Management Ltd lifted its position in Corbus Pharmaceuticals by 36.6% in the first quarter. Davy Global Fund Management Ltd now owns 435,285 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 116,617 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Corbus Pharmaceuticals in the first quarter valued at about $275,000. Hedge funds and other institutional investors own 25.40% of the company’s stock.

About Corbus Pharmaceuticals

(Get Rating)

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

Featured Stories

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.